Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The prospect of long-lasting drug-free remission for children and adults living with inflammatory arthritis is a step closer to becoming a reality, thanks to a new collaboration.

Woman with arthritis in her hand

The ARCADIA consortium has been enabled by £3m of funding from Arthritis UK. It brings together leaders in the field of inflammatory arthritis research from the UK and Italy to answer the important question of ‘When has remission been achieved?’ This could help people to safely stop their medications at the right time in the future.

There is no accurate biological test for determining when a patient with inflammatory arthritis is truly in a state of disease-free remission. This means that clinicians, alongside patients and their families, make treatment decisions without having a full picture of whether their arthritis has been resolved in the joints. Some individuals remain on treatment unnecessarily and others come off treatment only to quickly relapse.

Researchers and clinicians, from the Kennedy Institute, the Universities of Birmingham, Glasgow, Newcastle, Bristol, and Liverpool, alongside University College London Great Ormond Street Hospital, Kings College London and Università Cattolica del Sacro Cuore in Italy, aim to undertake clinical studies to accurately determine the true absence of disease.

Chris Buckley, Kennedy Professor of Translational Rheumatology and Director of Clinical Research at the Kennedy Institute explained: ‘The ARCADIA consortium is based on over a decade of collaboration between many of the organisations involved. History teaches that cure requires an understanding of cause. This partnership has a bold aim: to determine the cellular cause of inflammatory forms of arthritis across the lifespan so that we can deliver a cure for people with arthritis.’ 

Inflammatory arthritis includes several different types of arthritis including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). Collectively, it affects more than 1 in 100 people, not only in later life but also in childhood and adolescence. The disease can have a profound impact on daily life and sometimes leads to long term disability. It occurs when the immune system mistakenly attacks the joints, causing inflammation experienced as swelling, stiffness and pain.  

 

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences website.

 

 

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience